GENE ONLINE|News &
Opinion
Blog

2021-10-08| Asia-PacificCOVID-19

Samsung Biologics Inks CDMO Deal with Enzolytics on HIV and COVID-19 Antibodies

by Tyler Chen
Share To
(Photo: Samsung Biologics)

U.S.-based Enzolytics this week inked a deal with one of the world’s biggest CDMO firms. Samsung Biologics will help develop and manufacture Enzolytics’s HIV and SARS-CoV-2 targeting monoclonal antibodies to accelerate the latter’s IND filing process.

 

Provide End-to-End CDMO Service

The Korean firm will provide services involving the development and manufacture of cell lines and clinical drug products. Their R&D Center located in San Francisco will manufacture a stable cell line while the Incheon headquarters will produce related trial materials.

“We chose to partner with Samsung Biologics because of Samsung Biologics’ extensive experience and expertise in developing, producing, and manufacturing Monoclonal Antibodies for Infectious Diseases and Oncology,” said Dr. Gaurav Chandra, Enzolytics’ Chief Operating Officer Research and Development. 

“This partnership marks a pivotal milestone for Enzolytics to significantly advance the clinical development of our universal, durable, broadly neutralizing Monoclonal Antibodies and reduce time to the clinic and offer the much-needed treatment for patients.”

The pair might advance the collaboration to include other products from Enzolytics.

 

Use AI to Develop Antibodies for Infectious Diseases

Enzolytics will carry out AI analysis to develop antibodies that target immutable locations on viruses that cause infectious diseases. Their antibody development on HIV therapeutics is the most advanced among all the indications. ITV-1, Enzolytics’s HIV therapeutics, is currently on trial in the EU.

The firm is also developing treatments for rheumatoid arthritis, influenza A and B, tetanus, and hepatitis (A, B, C). Now, their technology is also implemented in developing antibodies against the COVID-19 virus.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
M&A
How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng
2021-12-06
After Raising $300 Million, China’s Abogen Hunkers Down on mRNA Covid-19 Vaccine with GenScript and Walvax
2021-12-01
Bioplus Interphex 2021: CDMOs- The Manufacturing Hub for the Next Generation of Therapeutics
2021-11-30
LATEST
Freenome Raises $300 Million Series D for Cancer-Detecting Multiomics Platform
2021-12-08
Novel RAGE Antagonist Stirs Hopes for Countering Diabetic Complications
2021-12-07
AstraZeneca Blocks Private Equity Buyout of Swedish Pharma Sobi
2021-12-06
Coherent Biopharma, WuXi STA Collab Takes a Crack at Peptide-Drug Conjugates
2021-12-06
How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng
2021-12-06
BeiGene launches IPO on Shanghai’s STAR market to raise $3B
2021-12-03
Novartis, UCB Take Aim at Parkinson’s Disease Under $1.65 Billion Collab
2021-12-03
EVENT
2021-12-13
63rd ASH ANNUAL MEETING AND EXPOSITION
Georgia, USA
2021-12-28
BIOHK2021
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!